RxDoctor Payments Data

Steven Edens, MD

Ophthalmology · West Palm Beach, FLNPI 1215468863

Payments from drug & device makers

$6,795in general payments, 2019–2025

Across 136 payments — averaging $49.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • AbbVie$877
  • Bausch & Lomb Americas Inc.$667
  • Tarsus Pharmaceuticals, Inc.$572
  • Harrow Eye, LLC$321
  • Sun Pharmaceutical Industries Inc.$283
  • plus $2K from 18 others

What the payments were for

  • Travel & lodging$1,27219%
  • Food & beverage$5,44780%
  • Education$761%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,795 in reported general payments places this provider in the 75th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$268,369
Medicare patients
471
Services billed
1,949

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost287$107,144
RestasisCyclosporine129$106,751
XiidraLifitegrast49$38,980
CombiganBrimonidine Tartrate/Timolol149$37,709
RocklatanNetarsudil Mesylat/Latanoprost77$29,537
Alphagan PBrimonidine Tartrate107$28,062
XdemvyLotilaner12$23,450
VyzultaLatanoprostene Bunod40$14,769
RhopressaNetarsudil Mesylate41$13,802
MieboPerfluorohexyloctane/Pf17$13,108
Cyclosporine31$10,753
Brimonidine Tartrate124$6,738
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol55$3,813
Travoprost29$3,378
Latanoprost311$3,006

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$877$279,667672 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo$667$66,857106 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$572$23,45012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in West Palm Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →